Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1212)	9/19/2002 2:34:46 PM
From: tuck	Read Replies (2) \| Respond to of 1784

IonWorks: >>head-to-head competitor with the Biacore/Axiom proposed entry?<< Yes, to some extent. Ion channel assays are subset of what ProCell could do by different means. Other competitors are Aurora, Aviva, Caliper, PKI, etc. What I haven't seen is much talk about how high the throughput of each system is. It's probably around in review articles, but the abstracts don't get to that subject. FWIW, MDCC also is releasing (or maybe already has released) a medium throughput version that does 50 - 100 test per day. It has estimated its ion channel market opportunity at $500 million and figures that 1500 labs are doing manual patch clamping. This from a conference call over six months old. Cheers, Tuck